CN109464651A - A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine - Google Patents
A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine Download PDFInfo
- Publication number
- CN109464651A CN109464651A CN201910002525.1A CN201910002525A CN109464651A CN 109464651 A CN109464651 A CN 109464651A CN 201910002525 A CN201910002525 A CN 201910002525A CN 109464651 A CN109464651 A CN 109464651A
- Authority
- CN
- China
- Prior art keywords
- cartilage
- healthy food
- amelioration
- metabolic disorder
- disease induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 201000010099 disease Diseases 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 34
- 235000001497 healthy food Nutrition 0.000 title claims abstract description 27
- 239000002131 composite material Substances 0.000 title claims abstract description 23
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 18
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims abstract description 17
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 16
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract description 16
- 229940056902 l- threonic acid Drugs 0.000 claims abstract description 16
- 229920002567 Chondroitin Polymers 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 14
- 230000008414 cartilage metabolism Effects 0.000 claims abstract description 13
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims abstract description 12
- 238000010521 absorption reaction Methods 0.000 claims abstract description 10
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 9
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 7
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 229920002101 Chitin Polymers 0.000 claims abstract description 4
- 235000010216 calcium carbonate Nutrition 0.000 claims abstract description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 18
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 210000001188 articular cartilage Anatomy 0.000 claims description 12
- 210000003321 cartilage cell Anatomy 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 8
- 230000018109 developmental process Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 210000004349 growth plate Anatomy 0.000 claims description 7
- 201000003068 rheumatic fever Diseases 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 244000046146 Pueraria lobata Species 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000010018 saw palmetto extract Substances 0.000 claims description 6
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 claims description 5
- 206010006811 Bursitis Diseases 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000004595 synovitis Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 4
- 210000002391 femur head Anatomy 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010007710 Cartilage injury Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 102000055008 Matrilin Proteins Human genes 0.000 claims description 3
- 108010072582 Matrilin Proteins Proteins 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000002785 anti-thrombosis Effects 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000005461 lubrication Methods 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000012666 negative regulation of transcription by glucose Effects 0.000 claims description 3
- 230000001151 other effect Effects 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 230000035699 permeability Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 108010048734 sclerotin Proteins 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 230000002929 anti-fatigue Effects 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000007875 Femur Head Necrosis Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- -1 sulfuric acid Aminoglucose sulfate Chemical compound 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 241000219781 Pueraria montana var. lobata Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002642 osteogeneic effect Effects 0.000 description 3
- USDAQJSRGJCNNX-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO USDAQJSRGJCNNX-JJKGCWMISA-N 0.000 description 2
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicines, it is related to field of pharmaceutical technology, the ingredient of the healthy food and composite medicine are as follows: polypeptide ammonia sugar chondroitin, l threonic acid, ethanolic extract and glucosamine sulfate, the main component of polypeptide ammonia sugar chondroitin is Glucosamine Sulphate, chondroitin sulfate, soy peptide powder, kudzu-vine root powder, calcium carbonate, microcrystalline cellulose and magnesium stearate, and the Glucosamine Sulphate is using chitin as raw material.The amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine, so that healthy food and composite medicine can not only reach the effect of common anti-inflammatory relieves the pain, and it is without side-effects, it can also be on the basis of improving the immunity of the human body, further increase human body cartilage position absorption of drugs, the problem for causing drug absorption rate low extremely because of cartilage metabolism thus can be reduced to a certain extent, so that just good physiotheraping effect can be played to human body cartilage position.
Description
Technical field
The present invention relates to field of pharmaceutical technology, specially a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and drug
Composition.
Background technique
Cartilage, that is, cartilaginous tissue, is made of cartilage cell and cytoplasm, endochondral matrix be in gel state, have compared with
Big toughness, cartilage are the connective tissues based on supporting function, are free of blood vessel and lymphatic vessel in cartilage, nutrients is by perichondrium
Vascular permeability into cytoplasm, then nutrition osteocyte.
There are many kinds of cartilage metabolism exceptional relevance diseases, common such as bursal synovitis, synovitis, rheumatic arthritis, class
Rheumatic arthritis and caput femoris necrosis etc., with the aging of China human mortality, arthritis has become a kind of extremely universal normal
See disease, knee cartilage metabolic disorder illness rate is 9.56% in population of China according to statistics, and 60 years old or more person is up to 78.5%, so
And usually only have the effect of anti-inflammatory analgetic for cartilage metabolism abnormal diseases drug produced at present, affected part can not be risen
To certain physiotherapy nursing effect, takes antiinflammation pain-stopping pharmaceutical for a long time and be easy to cause the digestive system and nervous system of body
The phenomenon that damage, causes body immunity to decline, and aggravates the state of an illness, can also cause distortion when serious, therefore need a kind of cartilage generation
Abnormal diseases improvement healthy food and composite medicine are thanked to solve the above problems.
Summary of the invention
(1) the technical issues of solving
In view of the deficiencies of the prior art, the present invention provides a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and medicines
Product composition solves and usually only has the effect of anti-inflammatory analgetic for cartilage metabolism abnormal diseases drug produced at present,
Can not play certain physiotherapy nursing effect to affected part, take for a long time antiinflammation pain-stopping pharmaceutical be easy to the digestive system of body and
The problem of nervous system causes to damage, and body immunity is caused to decline, and aggravates the state of an illness, can also cause distortion phenomenon when serious.
(2) technical solution
To achieve the above objectives, the technical solution adopted by the present invention is that: a kind of amelioration of disease induced by metabolic disorder in cartilage health
Food and composite medicine, the ingredient of the healthy food and composite medicine are as follows: polypeptide ammonia sugar chondroitin, l threonic acid, second
Alcohol extract and glucosamine sulfate, the main component of the polypeptide ammonia sugar chondroitin be Glucosamine Sulphate, chondroitin sulfate,
Soy peptide powder, kudzu-vine root powder, calcium carbonate, microcrystalline cellulose and magnesium stearate, and the Glucosamine Sulphate is to be with chitin
Raw material, then aminoglucose sulfate is made through sulphuric acid hydrolysis.
Preferably, the Glucosamine Sulphate is a kind of glycosaminoglycan, and glycosaminoglycan is the basic composition of articular cartilage
Ingredient can promote cartilage cell to synthesize, and increase the stability of cell membrane, protect cartilage cell, conditions of patients is delayed to be in progress, and
The Glucosamine Sulphate can manufacture proteoglycan lubrication softly turn-off, and the chondroitin sulfate is a kind of acidic mucopolysaccharide,
It is widely present in body in the form of proteoglycan, and the chondroitin sulfate can stimulate cartilage cell to synthesize collagen
And proteoglycan, the degradation for promoting the synthesis of cartilage matrix, repairing cartilaginous tissue, inhibiting cartilage enhance permeability, promote cartilage
Absorption to penetrating fluid, and the soy peptide powder by soybean protein hydrolyzed it is obtained be made of 3-6 amino acid it is low
Molecular polypeptide can promote absorption of the cartilage to minerals and microelement, and have the effects that antifatigue and adjusting is immune, and institute
Kudzu-vine root powder is stated with antithrombotic, reducing blood lipid and adjusting blood glucose and other effects, is enhanced human immunity, and the calcium member in the calcium carbonate
Element is the main component of sclerotin, can supplement calcium ion for human body, and the microcrystalline cellulose and the hard magnesium are as figuration
Agent.
Preferably, the l threonic acid has the function of that promote ossein to be formed synthesizes with albumen mucopolysaccharide, can protect
The normal configuration of articular cartilage delays the retrogression of articular cartilage, facilitates the growth and development of epiphyseal cartilage, improves epiphyseal cartilage
Interior osteogenetic process, and the l threonic acid can promote the healing of cartilage damage and the reparation of cartilaginous tissue, improve microcirculation system
The effects of uniting, delaying bone ageing process.
Preferably, the ethanolic extract be using saw palmetto fruit as raw material, using ethyl alcohol to the saw palmetto fruit into
Row extraction gained, the ethanolic extract have significant angiogenesis inhibiting effect.
Preferably, the free state aminoglucose in the glucosamine sulfate is located at human articular cartilage, is endochondral day
Right ingredient can alleviate the pain of arthritis initiation, and the glucosamine sulfate can stimulate the metabolism of cartilage, to inhibit joint
Scorching development.
Preferably, the composition contains the L- threonic acid of the polypeptide ammonia sugar chondroitin of 35-85 mass %, 4-24 mass %
The glucosamine sulfate of calcium, the ethanolic extract of 3-15 mass % and 1-5 mass %, and the total amount of these four ingredients is 100%.
Preferably, the composition is cartilage metabolism abnormal diseases Prevention and improvement health food composition.
Preferably, the cartilage metabolism abnormal diseases are bursal synovitis, synovitis, rheumatic arthritis, rheumatoid joint
Scorching or caput femoris necrosis.
Preferably, the composition is that composite medicine is used in the different disease treatment prevention and treatment of cartilage metabolism.
Preferably, the cartilage metabolism abnormal diseases are bursal synovitis, synovitis, rheumatic arthritis, rheumatoid joint
Scorching or caput femoris necrosis.
(3) beneficial effect
The beneficial effects of the present invention are:
1, the amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine pass through polypeptide ammonia sugar chondroitin, L-
Cooperation between threonic acid calcium, ethanolic extract and glucosamine sulfate, so that healthy food and composite medicine can not only reach
The effect of relieving the pain to common anti-inflammatory, and it is without side-effects, human body can also be further increased on the basis of improving the immunity of the human body
Cartilage position absorption of drugs, thus can reduce to a certain extent because cartilage metabolism causes drug absorption rate is low to ask extremely
Topic, so that just good physiotheraping effect can be played to human body cartilage position.
2, the amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine, by the way that polypeptide ammonia sugar cartilage is arranged
Element has layer protecting film by artificial synthesized polypeptide its surface of ammonia sugar chondroitin, so that polypeptide ammonia sugar chondroitin not will receive
Human body pepsin, pancreatin, amylase, digestive ferment and the secondary hydrolysis of acid-base material, can be directly entered small in the form of complete
Intestines are absorbed by small intestine, into human recycle system, play biological function, and polypeptide ammonia sugar chondroitin and other nutrients
Matter, which compares, to be had the characteristics that preferentially to be absorbed by the body, thus better nursing role can be played to human body cartilage, is effectively delayed
Conditions of patients progress, while drug can be also reduced to a certain extent to the irritation of digestion, by the way that sulfuric acid is arranged
Aminoglucose, the aminoglucose in glucosamine sulfate are concentrated mainly at human articular cartilage after being absorbed, be it is endochondral naturally at
Point, the pain of arthritis initiation can be alleviated, moreover it is possible to stimulate cartilage metabolic, to inhibit arthritic development, and sulfuric acid Portugal
Osamine is body manufacture and the important component for maintaining cartilage health, has the function of promoting regenerating bone or cartilage and safeguards cartilage health,
Glucosamine sulfate or a kind of natural anti-inflammatory analgetic substance simultaneously, can help arthritic to eliminate pain and without common anti-inflammatory
The secondary of analgesic drug product makees.
3, the amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine, by the way that l threonic acid, L- is arranged
Threonic acid calcium has the function of that promote ossein to be formed delays with the synthesis of albumen mucopolysaccharide, the normal configuration of Saving cortilage cartilage
The retrogression of articular cartilage；The growth and development for facilitating epiphyseal cartilage improves the interior osteogenetic process of epiphyseal cartilage, and l threonic acid
There is good affinity with the formed albumen of the endochondral ossein of human body, l threonic acid is enabled to play the function of carrier
Effect, and then calcium can be transported the target for reaching and specifying and generate bone in conjunction with ossein, pass through and ethanolic extract is set, ethyl alcohol extraction
It takes object that there is significant angiogenesis inhibiting effect, body immunity can be further enhanced.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
The present invention provides a kind of technical solution: a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and drug combination
Object, the ingredient of the healthy food and composite medicine are as follows: the main component of polypeptide ammonia sugar chondroitin 1, polypeptide ammonia sugar chondroitin 1 is
Glucosamine Sulphate, chondroitin sulfate, soy peptide powder, kudzu-vine root powder, calcium carbonate, microcrystalline cellulose and magnesium stearate, and sulfuric acid
Glucosamine is then through sulphuric acid hydrolysis aminoglucose sulfate, and Glucosamine Sulphate to be made using chitin as raw material
It is a kind of glycosaminoglycan, glycosaminoglycan is the ultimate constituent of articular cartilage, cartilage cell can be promoted to synthesize, and increases cell
The stability of film, protect cartilage cell, delay conditions of patients to be in progress, and Glucosamine Sulphate can manufacture proteoglycan lubrication it is soft
Joint, and chondroitin sulfate is a kind of acidic mucopolysaccharide, is widely present in body in the form of proteoglycan, and sulfuric acid is soft
Ossein can stimulate cartilage cell to synthesize collagen and proteoglycan, promote the synthesis of cartilage matrix, repair cartilaginous tissue, inhibit
The degradation of cartilage enhances permeability, promotes absorption of the cartilage to penetrating fluid, and soy peptide powder is by soybean protein through hydrolysis gained
To the low molecular polypeptide being made of 3-6 amino acid, can promote absorption of the cartilage to minerals and microelement, and have anti-
The effects of tired and adjusting is immune, and kudzu-vine root powder has antithrombotic, reducing blood lipid and adjusting blood glucose and other effects, enhances human immunity
Power, and the calcium constituent in calcium carbonate is the main component of sclerotin, and calcium ion, and microcrystalline cellulose and stearic acid can be supplemented for human body
Magnesium has the function of that promote ossein to be formed synthesizes with albumen mucopolysaccharide as excipient, l threonic acid 2, l threonic acid 2,
Can Saving cortilage cartilage normal configuration, delay the retrogression of articular cartilage, facilitate the growth and development of epiphyseal cartilage, improve epiphysis
The interior osteogenetic process of cartilage, and l threonic acid 2 can promote the healing of cartilage damage and the reparation of cartilaginous tissue, improve microcirculation
System, the effects of delaying bone ageing process, ethanolic extract 3 and glucosamine sulfate 4, ethanolic extract 3 are with saw palmetto fruit
Actually raw material, saw palmetto fruit is extracted using ethyl alcohol obtained by, there is ethanolic extract 3 significant angiogenesis to inhibit to make
With it is endochondral natural component that the free state aminoglucose in glucosamine sulfate 4, which is located at human articular cartilage, can alleviate pass
The scorching pain caused of section, glucosamine sulfate 4 can stimulate the metabolism of cartilage, to inhibit arthritic development.
Embodiment:
The embodiment of the present invention is described in detail below, so that advantages and features of the invention are easier to be understood,
It apparent is explicitly defined to be made to protection scope of the present invention.
Embodiment: the Production Example of capsule medicament
According to following prescriptions, it is sufficiently stirred by conventional method with powder, mixes a variety of materials, and polypeptide ammonia sugar chondroitin
1, l threonic acid 2, ethanolic extract 3 and glucosamine sulfate 4 need to carry out between adjustment according to the vital signs of living body
Proportional amount composition.
Test example: the effect test carried out using model of rheumatoid arthritis animal, and in whole experiment process, animal
It freely ingests and drinks water, 20 DEG C~23 DEG C of room temperature, relative humidity 60%~63%.
Experimental method: it first after a week using the feeding of basal feed adaptability, is weighed using electronic balance, and according to body
Be randomly divided into three groups again, i.e., traditional sample, in traditional sample mix GCP with reach 970 ㎎/kg body weight/day feed and
Blend compositions are in traditional sample to reach 620 ㎎/kg body weight/day feed.
Pathological examination shows: for traditional sample group after the raising for carrying out week age, the osteoarticular sites of most animals are equal
With different degrees of swelling phenomenon, and their normal activity is affected because of the pain of Bones and joints, while also causing to take the photograph
Enter amount and the state of mind all in downward trend；The sample group of GCP is mixed with after the nursing by week age, it is only small
The osteoarticular sites of Some Animals have slight swelling phenomenon, but still have toy internal drug consumption in one day in part complete
Period in mental status be gradually reduced because of the discomfort of Bones and joints, be mixed with the sample group of composition and carrying out raising one week
Afterwards, the weight of most of toy all has growth in varying degrees as the result is shown, and osteoarticular sites be discovery have it is swollen
Swollen phenomenon, is verified by many experiments, and composition of the invention effectively inhibits the pathologic progress of rheumatic arthritis, and not
It was found that any side effect, cartilage position, which is in, slowly restores state.
Above specific embodiment has carried out further in detail the purpose of the present invention, technical scheme and beneficial effects
Illustrate, it should be understood that be not intended to restrict the invention the above is only a specific embodiment of the invention, it is all at this
Within the spirit and principle of invention, any modification, equivalent substitution, improvement and etc. done should be included in protection model of the invention
Within enclosing.
Claims (10)
1. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine, it is characterised in that the healthy food and medicine
The ingredient of product composition are as follows: polypeptide ammonia sugar chondroitin (1), l threonic acid (2), ethanolic extract (3) and glucosamine sulfate
(4), the main component of the polypeptide ammonia sugar chondroitin (1) is Glucosamine Sulphate, chondroitin sulfate, soy peptide powder, pueraria lobata
Powder, calcium carbonate, microcrystalline cellulose and magnesium stearate, and the Glucosamine Sulphate is using chitin as raw material, then through sulfuric acid
Aminoglucose sulfate is made in hydrolysis.
2. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1 and composite medicine, special
Sign is: the Glucosamine Sulphate is a kind of glycosaminoglycan, and glycosaminoglycan is the ultimate constituent of articular cartilage, can
Promote cartilage cell's synthesis, increase the stability of cell membrane, protects cartilage cell, delay conditions of patients to be in progress, and the sulfuric acid
Glucosamine can manufacture proteoglycan lubrication softly turn-off, and the chondroitin sulfate is a kind of acidic mucopolysaccharide, more with albumen
The form of sugar is widely present in body, and the chondroitin sulfate can stimulate cartilage cell's synthesis collagen and albumen more
Sugar, the degradation for promoting the synthesis of cartilage matrix, repairing cartilaginous tissue, inhibiting cartilage, enhances permeability, promotes cartilage to penetrating fluid
Absorption, and the soy peptide powder by soybean protein through hydrolyzing the obtained low molecular polypeptide being made of 3-6 amino acid,
It can promote absorption of the cartilage to minerals and microelement, and have the effects that antifatigue and adjusting is immune, and the kudzu-vine root powder
It with antithrombotic, reducing blood lipid and adjusting blood glucose and other effects, enhances human immunity, and the calcium constituent in the calcium carbonate is sclerotin
Main component, calcium ion can be supplemented for human body, and the microcrystalline cellulose and the hard magnesium are as excipient.
3. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1 and composite medicine, special
Sign is: the l threonic acid (2) have the function of promote ossein formed and albumen mucopolysaccharide synthesis, can Saving cortilage it is soft
The normal configuration of bone delays the retrogression of articular cartilage, facilitates the growth and development of epiphyseal cartilage, improves the interior skeletonization of epiphyseal cartilage
Process, and the l threonic acid (2) can promote the healing of cartilage damage and the reparation of cartilaginous tissue, improve microcirculqtory system,
The effects of delaying bone ageing process.
4. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1 and composite medicine, special
Sign is: the ethanolic extract (3) is extracted using ethyl alcohol to the saw palmetto fruit using saw palmetto fruit as raw material
Gained, the ethanolic extract (3) have significant angiogenesis inhibiting effect.
5. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1 and composite medicine, special
Sign is: the free state aminoglucose in the glucosamine sulfate (4) is located at human articular cartilage, be it is endochondral naturally at
Point, the pain of arthritis initiation can be alleviated, the glucosamine sulfate (4) can stimulate the metabolism of cartilage, to inhibit joint
Scorching development.
6. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1 and composite medicine, special
Sign is: the composition contains the l threonic acid of the polypeptide ammonia sugar chondroitin (1) of 35-85 mass %, 4-24 mass %
(2), the glucosamine sulfate (4) of the ethanolic extract (3) of 3-15 mass % and 1-5 mass %, and the total amount of these four ingredients
It is 100%.
7. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1-6 and drug combination
Object, it is characterised in that: the composition is cartilage metabolism abnormal diseases Prevention and improvement health food composition.
8. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 7 and composite medicine, special
Sign is: the cartilage metabolism abnormal diseases are bursal synovitis, synovitis, rheumatic arthritis, rheumatoid arthritis or femur
Head necrosis.
9. a kind of amelioration of disease induced by metabolic disorder in cartilage healthy food according to claim 1-6 and drug combination
Object, it is characterised in that: the composition is that composite medicine is used in the different disease treatment prevention and treatment of cartilage metabolism.
10. according to a kind of described in any item amelioration of disease induced by metabolic disorder in cartilage healthy food of claim 9 and drug combination
Object, it is characterised in that: the cartilage metabolism abnormal diseases are bursal synovitis, synovitis, rheumatic arthritis, rheumatoid arthritis
Or caput femoris necrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910002525.1A CN109464651A (en) | 2019-01-02 | 2019-01-02 | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910002525.1A CN109464651A (en) | 2019-01-02 | 2019-01-02 | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109464651A true CN109464651A (en) | 2019-03-15 |
Family
ID=65677058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910002525.1A Withdrawn CN109464651A (en) | 2019-01-02 | 2019-01-02 | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109464651A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112535706A (en) * | 2020-12-16 | 2021-03-23 | 解中胜 | Medicine and food dual-purpose powder for repairing joints and preparation method and application thereof |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
-
2019
- 2019-01-02 CN CN201910002525.1A patent/CN109464651A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112535706A (en) * | 2020-12-16 | 2021-03-23 | 解中胜 | Medicine and food dual-purpose powder for repairing joints and preparation method and application thereof |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN103404865B (en) | Nutritional meal replacement powder with effect of reducing weight and fat and preparation method thereof | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN102090561A (en) | Artemisia leaf nutritional chewable tablet and preparation method thereof | |
| CN104605226A (en) | Healthcare product with function of increasing bone mineral density | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN108741099A (en) | One kind contributing to comfortable alimentation composition in joint and its preparation method and application | |
| CN111802631A (en) | Green multi-vitamin nutrient and preparation method thereof | |
| CN103734581B (en) | Yak milk polypeptide nutrient powder being applicable to postoperative crowd's rehabilitation and preparation method thereof | |
| CN114365850A (en) | Polypeptide composition with function of improving cartilage health and preparation method thereof | |
| CN113826908A (en) | Functional product with physique strengthening and anti-aging effects and preparation method thereof | |
| CN107252099A (en) | A kind of health food for improving osteoarthritic inflammation and preparation method thereof | |
| US20080312149A1 (en) | Health Food and Pharmaceutical Composition for Amelioration of Disease Induced by Metabolic Disorder in Cartilage | |
| CN111820348A (en) | Saussurea involucrata culture ossein peptide composite fruit juice and preparation method thereof | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| WO2016043668A1 (en) | A composition suitable for vegetarians providing calcium supplementation as well as gout prevention and treatment and the method of preparation thereof | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| CN103238839A (en) | Food composition containing collagen used for maintaining joints | |
| CN114698850A (en) | Formula and preparation method of egg membrane peptide composition | |
| CN114617267A (en) | Reinforced composite bone peptide and preparation method and application thereof | |
| CN109805235B (en) | Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food | |
| CN103494201B (en) | Osteoarticular disease care product of L-ascorbyl dipalmitate | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190315 |